Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats

British Journal of Pharmacology

Volumn 145, Issue 8, 2005, Pages 1035-1044

  Hatip Al Khatib, Izzettin ^a,b   Iwasaki, Katsunori ^b   Yoshimitsu, Yoshitaka ^b   Arai, Takashi ^b   Egashira, Nobuaki ^b   Mishima, Kenichi ^b   Ikeda, Tomoaki ^b   Fujiwara, Michihiro ^b  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Acetylcholine; Alzheimer's disease; Donepezil; Microdialysis; Monoamines; Ventral hippocampus; Zanapezil

Indexed keywords

3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; ADRENALIN; CATECHOLAMINE; DONEPEZIL; DOPAMINE; HOMOVANILLIC ACID; INDOLEAMINE; MONOAMINE; NORADRENALIN; NORMETADRENALIN; SEROTONIN; ZANEPEZIL;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ACETYLCHOLINE BRAIN LEVEL; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; CATECHOLAMINE BRAIN LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN BRAIN LEVEL; OXIDATION; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

ACETYLCHOLINE; ADMINISTRATION, ORAL; ANIMALS; BENZAZEPINES; BIOGENIC MONOAMINES; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIPPOCAMPUS; INDANS; MALE; MICRODIALYSIS; PIPERIDINES; RATS; RATS, WISTAR; TIME FACTORS;

EID: 30544452029     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706288     Document Type: Article

References (56)

1. ABE, Y., AOYAGI, A., HARA, T., ABE, K., YAMAZAKI, R., KUMAGAE, Y., NARUTO, S., KOYAMA, K., MARUMOTO, S., TAGO, K., TODA, N., TAKAMI, K., YAMADA, N., ORI, M., KOGEN, H. & KANEKO, T. (2003). Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. J. Pharmacol. Sci., 93, 95-105.
2. BALDUCCI, C., NURRA, M., PIETROPOLI, A., SAMANIN, R. & CARLI, M. (2003). Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635. Psychopharmacology (Berlin), 167, 28-36.
3. BARNES, C.A., MELTZER, J., HOUSTON, F., ORR, G., MCGANN, K. & WENK, G.L. (2000). Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience, 99, 17-23.
4. BERTHIER, M.L., PUJOL, J., GIRONELL, A., KULISEVSKY, J., DEUS, J., HINOJOSA, J. & SORIANO-MAS, C. (2003). Beneficial effect of donepezil on sensorimotor function after stroke. Am. J. Phys. Med. Rehabil., 82, 725-729.
5. BRUERA, E., STRASSER, F., SHEN, L., PALMER, J.L., WILLEY, J., DRIVER, L.C. & BURTON, A.W. (2003). The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot stud. J. Pain Symptom Manage., 26, 1049-1054.
6. CHEN, Z., XU, A.J., LI, R. & WEI, E.Q. (2002). Reversal of scopolamine-induced spatial memory deficits in Morris water maze by TAK-147. Acta Pharmacol. Sin., 19, 27-30.
7. 2+ signals and neurotransmitter release. Mol. Pharmacol., 64, 1217-1226.
8. DRINGENBERG, H.C. (2000). Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav. Brain Res., 115, 235-249.
9. FEINSTEIN, D.L., HENEKA, M.T., GAVRILYUK, V., DELLO RUSSO, C., WEINBERG, G. & GALEA, E. (2002). Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int., 41, 357-365.
10. FINKEL, S.I., MINTZER, J.E., DYSKEN, M., KRISHNAN, K.R., BURT, T. & MCRAE, T. (2004). A randomized, placebo controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int. J. Geriatr. Psychiatry, 19, 9-18.
11. GALEA, E., HENEKA, M.T., RUSSO, D.C. & FEINSTEIN, D.L. (2003). Intrinsic regulation of brain inflammatory responses. Cell Mol. Neurobiol., 23, 625-635.
12. GIACOBINI, E., ZHU, X.D., WILLIAMS, E. & SHERMAN, K.A. (1996). The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology, 35, 205-211.
13. GILMAN, S., KOEPPE, R.A., LITTLE, R., AN, H., JUNCK, L., GIORDANI, B., PERSAD, C., HEUMANN, M. & WERNETTE, K. (2004). Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann. Neurol., 55, 774-780.
14. GOTTFRIES, C.G. (1990). Neurochemical aspects on aging and diseases with cognitive impairment. J. Neurosci. Res., 27, 541-547.
15. HATIP-AL-KHATIB, I., ARAI, T., EGASHIRA, N., IWASAKI, K. & FUJIWARA, M. (2004). Comparison of the effect of TAK-147 (Zanapezil) and E-2020 (Donepezil) on extracellular acetylcholine level and blood flow in the ventral hippocampus of freely moving rats. Brain Res., 1012, 169-176.
16. HAYSLETT, R.L. & TIZABI, Y. (2003). Effects of donepezil on DOI-induced head twitch response in mice: implications for Tourette syndrome. Pharmacol. Biochem. Behav., 76, 409-415.
17. HENEKA, M.T., GALEA, E., GAVRILUYK, V., DUMITRESCU-OZIMEK, L., DAESCHNER, J., O'BANION, M.K., WEINBERG, G., KLOCKGETHER, T. & FEINSTEIN, D.L. (2002). Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci., 22, 2434-2442.
18. HIKIDA, T., KITABATAKE, Y., PASTAN, I. & NAKANISHI, S. (2003). Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc. Natl. Acad. Sci. U.S.A., 100, 6169-6173.
19. HIRAI, K., KATO, K., NAKAYAMA, T., HAYAKO, H., ISHIHARA, Y., GOTO, G. & MIYAMOTO, M. (1997). Neurochemical effects of 3-[1-(phenylmethyl)-4- piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor in rats. J. Pharmacol. Exp. Ther., 280, 1261-1269.
20. HOOGENDIJK, W.J., FEENSTRA, M.G., BOTTERBLOM, M.H., GILHUIS, J., SOMMER, I.E., KAMPHORST, W., EIKELENBOOM, P. & SWAAB, D.F. (1999). Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann. Neurol., 45, 82-91.
21. ISHIHARA, Y., GOTO, G. & MIYAMOTO, M. (2000). Central selective acetylcholinesterase inhibitor with neurotrophic activity: structure-activity relationships of TAK-147 and related compounds. Curr. Med. Chem., 7, 341-354.
22. ISOMA, K., ISHIKAWA, M., OHTA, M., OGAWA, Y., HASEGAWA, H., KOHDA, T. & KAMEI, J. (2002). Effects of T-82, a new quinoline derivative, on cholinesterase activity and extracellular acetylcholine concentration in rat brain. Jpn. J. Pharmacol., 88, 206-212.
23. KATO, K., HAYAKO, H., ISHIHARA, H., MARUI, Y., IWANE, M. & MIYAMOTO, M. (1999). TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci. Lett., 260, 5-8.
24. KISS, J.P., VIZI, E.S. & WESTERINK, B.H. (1999). Effect of neostigmine on the hippocampal noradrenaline release: role of cholinergic receptors. Neuroreport, 10, 81-86.
25. KLOTZ, L., SASTRE, M., KREUTZ, A., GAVRILYUK, V., KLOCKGETHER, T., FEINSTEIN, D.L. & HENEKA, M.T. (2003). Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J. Neurochem., 86, 907-916.
26. KOSASA, T., KURIYA, Y., MATSUI, K. & YAMANISHI, Y. (2000). Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Eur. J. Pharmacol., 389, 173-179.
27. LEHERICY, S., BRANDEL, J.P., HIRSCH, E.C., ANGLADE, P., VILLARES, J., SCHERMAN, D., DUYCKAERTS, C., JAVOY-AGID, F. & AGID, Y. (1994). Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res., 659, 1-9.
28. MARTIGNONI, E., BONO, G., BLANDINI, F., SINFORIANI, E., MERLO, P. & NAPPI, G. (1991). Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl. J. Neural Transm-Park., 3, 15-25.
29. MASUDA, Y. & KAWAMURA, A. (2003). Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability. J. Cardiovasc. Pharmacol., 41 (Suppl 1), S67-S71.
30. MATTHEWS, K.L., CHEN, C.P., ESIRI, M.M., KEENE, J., MINGER, S.L. & FRANCIS, P.T. (2002). Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry, 51, 407-416.
31. MISANE, I. & OGREN, S.O. (2003). Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology, 28, 253-264.
32. MIYAMOTO, M., TAKAHASHI, H., KATO, K., HIRAI, K., ISHIHARA, Y. & GOTO, G. (1996). Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5- tetrahydro-1-H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models. J. Pharmacol. Exp. Ther., 277, 1292-1304.
33. MOREY, C.E., CILO, M., BERRY, J. & CUSICK, C. (2003). The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study. Brain Injury, 17, 809-815.
34. NAKAYAMA, T., TAKAHASHI, H., MIYAMOTO, M., GOTO, G. & NAGAI, Y. (1996). Effect of TAK-147, a novel AChE inhibitor, on cerebral energy metabolism. Neurobiol. Aging, 17, 849-857.
35. NOBILI, F., VITALI, P., CANFORA, M., GIRTLER, N., DE LEO, C., MARIANI, G., PUPI, A. & RODRIGUEZ, G. (2002). Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin. Neurophysiol., 113, 1241-1248.
36. OGURA, H., KOSASA, T., KURIYA, Y. & YAMANISHI, Y. (2000). Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find. Exp. Clin. Pharmacol., 22, 609-613.
37. OGURA, H., KOSASA, T., KURIYA, Y. & YAMANISHI, Y. (2001). Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. Eur. J. Pharmacol., 415, 157-164.
38. OHARA, K., KONDO, N. & OHARA, K. (1998). Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 22, 311-317.
39. PARNETTI, L., GAITI, A., REBOLDI, G.P., SANTUCCI, C., MECOCCI, P., BRUNETTI, M., CADINI, D. & SENIN, U. (1992). CSF monoamine metabolites in old age dementias. Mol. Chem. Neuropathol., 16, 143-157.
40. PAXINOS, G. & WATSON, C. (1998). The Rat Brain Stereotaxic Coordinates, 4th edn., New York: Academic Press.
41. PERRY, E.K., MARSHALL, E., THOMPSON, P., MCKEITH, I.G., COLLERTON, D., FAIRBAIRN, A.F., FERRIER, I.N., IRVING, D. & PERRY, R.H. (1993). Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features. J. Neural Transm.-Park., 6, 167-177.
42. REID, R.T. & SABBAGH, M.N. (2003). Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro. J. Alzheimer's Dis., 5, 429-436.
43. ROGERS, D.C. & HAGAN, J.J. (2001). 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berlin), 158, 114-119.
44. SCALI, C., CASAMENTI, F., BELLUCCI, A., COSTAGLI, C., SCHMIDT, B. & PEPEU, G. (2002). Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J. Neural Transm., 109, 1067-1080.
45. SCHRAG, A. (2004). Psychiatric aspects of Parkinson's disease-an update. J. Neurol. 251, 795-804.
46. SHU, S.Y., WU, Y.M., BAO, X.M., WEN, Z.B., HUANG, F.H., LI, S.X., FU, Q.Z. & NING, Q. (2002). A new area in the human brain associated with learning and memory: immunohistochemical and functional MRI analysis. Mol. Psychiatry, 7, 1018-1022.
47. SJOGREN, M., MINTHON, L., PASSANT, U., BLENNOW, K. & WALLIN, A. (1998). Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol. Aging, 19, 379-384.
48. SPENCER, T. & BIEDERMAN, J. (2002). Non-stimulant treatment for attention-deficit/hyperactivity disorder. J. Atten. Disord., 6 (Suppl 1), S109-S119.
49. STRYJER, R., STROUS, R.D., BAR, F., WERBER, E., SHAKED, G., BUHIRI, Y., KOTLER, M., WEIZMAN, A. & RABEY, J.M. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin. Neuropharmacol., 26, 12-17.
50. UMEGAKI, H., IKARI, H., NAKAHATA, H., YOSHIMURA, J., ENDO, H., YAMAMOTO, T. & IGUCHI, A. (2000). Low plasma epinephrine in elderly female subjects of dementia of Alzheimer type. Brain Res., 858, 67-70.
51. WALLIN, A., CARLSSON, A., EKMAN, R., GOTTFRIES, C.G., KARLSSON, I., SVENNERHOLM, L. & WIDERLOV, E. (1991). Hypothalamic monoamines and neuropeptides in dementia. Eur. Neuropsychopharmacol., 1, 165-168.
52. WILKINSON, D., DOODY, R., HELME, R., TAUBMAN, K., MINTZER, J., KERTESZ, A. & PRATT, R.D. (2003). Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology, 61, 479-486.
53. WU, Y.H., FEENSTRA, M.G., ZHOU, J.N., LIU, R.Y., TORANO, J.S., VAN KAN, H.J., FISCHER, D.F., RAVID, R. & SWAAB, D.F. (2003). Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J. Clin. Endocrinol. Metab., 88, 5898-5906.
54. XU, A., CHEN, Z., YANAI, K., HUANG, Y. & WEI, E. (2002). Effect of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl) -1-propanone fumarate, a novel acetylcholinesterase inhibitor, on spatial cognitive impairment induced by chronic cerebral hypoperfusion in rats. Neurosci. Lett., 331, 33-36.
55. YANG, Y. & SCHMITT, H.P. (2001). Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol. (Berlin), 101, 256-270.
56. ZHANG, L., ZHOU, F.M. & DANI, J.A. (2004). Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol. Pharmacol., 66, 538-544.